South Korea's MFDS receives NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia | Optometry Times - Clinical News

Published on November 5, 2025
The submission marks the first ex-US regulatory submission for Brimochol PF.
Continue reading on website
Other news

Fitting the future: How technology is refining specialty lens care | Optometry Times - Clinical News

November 5, 2025
Today’s tools let clinicians fine-tune fits with accuracy, while solving old challenges and unlocking complex optical corrections.

Tarsus Achieves Strong Third Quarter Financial Results, Driven by Growing Xdemvy Prescriptions

November 6, 2025
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, has announced financial results for the third quarter ended September 30, 2025. Net product sales for the quarter were reported at $118.7 million, compared with $48.1 million for the same period in 2024, driven by more than 103,0